Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT.

Autor: Fernández S; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain., Cereceda L; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain.; Pathology Department MD Anderson Cancer Center Madrid Madrid Spain., Díaz E; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain., Figueroa S; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain.; Pathology Department MD Anderson Cancer Center Madrid Madrid Spain., Reguera L; Nuclear Medicine Department MD Anderson Cancer Center Madrid Madrid Spain., Menéndez V; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain., Solórzano JL; Pathology Department MD Anderson Cancer Center Madrid Madrid Spain., Montalbán C; Hematology Department MD Anderson Cancer Center Madrid Madrid Spain., Estévez M; Hematology Department MD Anderson Cancer Center Madrid Madrid Spain., García JF; Translational Research, Fundación MD Anderson International España S.L. Madrid Madrid Spain.; Pathology Department MD Anderson Cancer Center Madrid Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2023 Nov 29; Vol. 5 (1), pp. 70-75. Date of Electronic Publication: 2023 Nov 29 (Print Publication: 2024).
DOI: 10.1002/jha2.826
Abstrakt: The value of circulating tumor DNA (ctDNA) as a biomarker of disease activity in classic Hodgkin lymphoma (cHL) patients has not yet been well established. By profiling primary tumors and ctDNA, we identified common variants between primary tumors and longitudinal plasma samples in most of the cases, confirming high spatial and temporal heterogeneity. Although ctDNA analyses mirrored HRS cell genetics overall, the prevalence of variants shows that none of them can be used as a single biomarker. Conversely, the estimation of hGE/mL, based on measures of total ctDNA, reflects disease activity and is almost perfectly correlated with standard parameters such as PET/CT that are associated with refractoriness.
Competing Interests: The authors declare no competing financial interests.
(© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: